Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Core Insights - Palatin Technologies, Inc. has completed its Phase 2 clinical study (BMT-801) for the co-administration of MC4R bremelanotide and GLP-1/GIP tirzepatide aimed at treating obesity, with final data collection expected soon [1][2][3] Group 1: Clinical Study Details - The Phase 2 BMT-801 study enrolled 113 patients, with 96 patients randomized, exceeding the initial target of 60 patients due to strong demand [2] - The primary endpoint of the study is to demonstrate the safety and efficacy of the combination treatment in reducing body weight [3] - Topline data results from the study are anticipated to be released later this quarter [2][3] Group 2: Mechanism and Importance - The melanocortin 4 receptor (MC4R) is crucial for appetite regulation, and its modulation may provide new treatment avenues for obesity [4] - MC4R agonists are seen as a promising target for obesity treatments, potentially offering additive and synergistic effects when combined with GLP-1/GIP agonists [3][4] Group 3: Company Overview - Palatin Technologies focuses on developing first-in-class medicines that modulate the melanocortin receptor system, addressing significant unmet medical needs [6] - The company aims to form marketing collaborations with industry leaders to maximize the commercial potential of its products [6]